Mirtazapine in the treatment of panic disorder: An open-label trial

International Clinical Psychopharmacology

Volumn 18, Issue 1, 2003, Pages 35-38

  Sarchiapone, M ^a   Amore, M ^b   De Risio, S ^a   Carli, Vladimir ^a,e   Faia, V ^a   Poterzio, F ^d   Balista, C ^b   Camardese, G ^a   Ferrari, G ^c  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^e NONE   (Italy)

Author keywords

Antidepressant; Anxiolytic; Mirtazapine; Noradrenergic; Open label trial; Panic disorder; Serotoninergic

Indexed keywords

MIRTAZAPINE;

ADULT; AGORAPHOBIA; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DROWSINESS; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL PATIENT; PANIC; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCHOMETRY; SEDATION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; TREATMENT OUTCOME; WEIGHT GAIN;

ADULT; COMORBIDITY; DEPRESSIVE DISORDER; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; MALE; MIANSERIN; MIDDLE AGED; PANIC DISORDER; PSYCHOMETRICS; TREATMENT OUTCOME;

EID: 0037242757     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200301000-00006     Document Type: Article

References (25)

1. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Association.
2. Asnis GM, Hameedi FA, Goddard AW, et al. (2001). Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients. Psychiatry Res 5:1-14.
3. Ballenger JC, Wheadon DE, Steiner M, et al. (1998). Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 155:36-42.
4. Benkert O, Szegedi A, Kohnen R (2000). Mirtazapine compared with Paroxetine in Major Depression. J Clin Psychiatry 61:656-663.
5. Boshuisen ML, Slaap BR, Vester-Blokland ED, den Boer JA (2001). The effect of mirtazapine in panic disorder: an open label pilot study with a single-blind placebo run-in period. Int Clin Psychopharmacol 16:363-368.
6. Carpenter LL, Leon Z, Yasmin S, et al. (1999). Clinical experience with mirtazapine in the treatment of panic disorder. Annals Clinical Psychiatry 11:81-86.
7. Charney DS, Woods SW, Krystal JH, et al. (1992). Noradrenergic neuronal dysregulation in panic disorder: the effects of intravenous yohimbine and clonidine in panic disrder patients. Acta Psychiatr Scand 86:273-282.
8. Den Boer JA, Westenberg HGM (1996). Involvement of serotonin receptor subtypes in panic disorder: a critical appraisal of the evidence. In: Westenberg HGM, Den Boer JA, Murphy DL (editors): Advances in the Neurobiology of Anxiety Disorders. Chichester: John Wiley and Sons; pp.139-172.
9. First MB, Spitzer RL, Gibbon M, Williams J BW (1997). Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I)-Clinical Version. Washington, DC: American Psychiatric Press.
10. Goodnick PJ, Puig A, DeVane CL, et al. (1999). Mirtazapine in major depression with comorbid generalized anxiety disorder. J Clin Psychiatry 60:446-448.
11. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
12. Hamilton M (1967). Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278-296.
13. Jefferson JW (1997). Antidepressants in panic disorder. J Clin Psychiatry 58(suppl. 2):20-25.
14. Ninan PT (2000). Use of venlafaxine in other psychiatric disorders. Depress Anxiety 12(suppl. 1):90-94.
15. Nutt DJ (1999). Care of depressed patients with anxiety symptoms. J Clin Psychiatry 60(suppl. 17):23-27.
16. Papp LA, Sinha SS, Martinez JM, Coplan JD, Amchin J, Gorman JM (1998). Low-dose venlafaxine treatment in panic disorder. Psychopharmacol Bull 34:207-209.
17. Perna G, Bertani A, Caldirola D, Smeraldi E, Bellodi L (2001). A comparison of citalopram and paroxetine in the treatment of panic disorder: a randomized, single-blind study. Pharmacopsychiatry 34:85-90.
18. Price LH, Goddard AW, Barr L, et al. (1995). Pharmacological challenges in anxiety disorders. In: Bloom FE, Kupfer DJ (editors): Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press; pp. 387-397.
19. Rapaport MH, Pollack M, Wolkow R, Mardekian J, Clary C (2000). Is placebo response the same as drug response in panic disorder? Am J Psychiatry 157:1014-1016.
20. Shear MK, Brown TA, Barlow DH, et al. (1997). Multicenter collaborative panic disorder severity scale. Am J Psychiatry, 154:1571-1575.
21. Smith WT, Glaudin V, Panagides J, et al. (1990). Mirtazapine versus amitriptyline versus placebo in the treatment of major depressive disorder. Psychopharmacol Bull 26:191-196.
22. Stahl S, Zivkov M, Reimitz PE, Panagides J, Hoff W (1997). Meta-analysis of randomized, double blind, placebo-controlled, efficacy and safety studies of mirtazapine versus amitriptyline in major depression. Acta Psychiatr Scand 96(suppl. 391):22-30.
23. Thase ME (1999). Antidepressant treatment of the depressed patient with insomnia. J Clin Psychiatry 60(suppl. 17):28-31.
24. Wheatley D, Van Moffaert M, Timmermann L, Kremer C (1998). Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. J Clin Psychiatry 59:306-312.
25. Winokur A, Sateia MJ, Hayes JB, Bayles-Dazet W, MacDonald MM, Gary KA (2000). Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: a pilot study. Biol Psychiatry 48:75-78.